A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease

Figure 6

Forest plots of the relative risk of developing any adverse event (a), a serious adverse event (b), or an adverse event leading to withdrawal following the administration of pramipexole (c). Treatment with pramipexole did not increase the incidence of adverse events when compared with the use of either a placebo. The included studies were homogeneous (a, b) or had moderate heterogeneity (c).

(a)

(b)

(c)